Drug Policy Archives

Federal agencies’ next moves to accelerate the availability of psychedelic therapies

Federal agencies’ next moves to accelerate the availability of psychedelic therapies

By Geoffrey Lawrence

Federal agencies have responded to Trump's executive order on psychedelic therapies with a series of related announcements.

After moves to protect medical marijuana, Trump asks Congress to save hemp

After moves to protect medical marijuana, Trump asks Congress to save hemp

By Michelle Minton

Trump’s medical marijuana rescheduling is historic—but many questions remain

Trump’s medical marijuana rescheduling is historic—but many questions remain

By Michelle Minton and Geoffrey Lawrence

States react to nitrous oxide deaths with unnecessary, unworkable bans

States react to nitrous oxide deaths with unnecessary, unworkable bans

By Hanna Liebman Dershowitz

How Trump’s executive order could accelerate widespread access to psychedelic therapies

How Trump’s executive order could accelerate widespread access to psychedelic therapies

By Leonard Gilroy and Geoffrey Lawrence

Tennessee bills would eliminate the state’s legal kratom market

Commentary by Sephria Reynolds-Tanner

Colorado becomes the first state to address wrongful arrests and convictions caused by unreliable field drug tests

Commentary by Vittorio Nastasi and David L. Morgan

Why isn’t the Food and Drug Administration celebrating the decline in youth tobacco use?

Commentary by Guy Bentley

Separating fact from fear in drug-related child welfare policy

Commentary by Layal Bou Harfouch and Hanna Liebman Dershowitz

Model legislation for audit requirements for opioid settlement fund recipients

Commentary by Geoffrey Lawrence, Mariana Trujillo and Layal Bou Harfouch

States should prioritize private service providers for the opioid settlement funds

Commentary by Layal Bou Harfouch, Mariana Trujillo and Adrian Moore

Mississippi and West Virginia to join Texas ibogaine initiative

Commentary by Geoffrey Lawrence

South Carolina Senate Bill 519 would establish a lower excise tax rate for heated tobacco products

Testimony by Guy Bentley

Psychedelics Policy Newsletter: States pursue psilocybin expansion, Trump administration denies drug fast-tracking, and more

Psychedelics Policy Newsletter by Gregory Ferenstein

Drug Policy Policy Studies

Proposed Model Policy: “Veterans Mental Health Innovations Act”

Backgrounder by Kaitlyn Boecker, Geoffrey Lawrence and Leonard Gilroy

Model legislation would authorize groundbreaking research into ibogaine for mental health

Backgrounder by Kaitlyn Boecker, Geoffrey Lawrence and Leonard Gilroy

Ibogaine could transform public spending on opioid treatment

Backgrounder by Madison Carlino

Drug Policy Newsletters

Psychedelics Policy Newsletter: States pursue psilocybin expansion, Trump administration denies drug fast-tracking, and more

Psychedelics Policy Newsletter by Gregory Ferenstein

Psychedelics Policy Newsletter: New real-world psilocybin study, ibogaine educational materials, and more

Psychedelics Policy Newsletter by Gregory Ferenstein

Subscribe to the Psychedelics Policy Newsletter

Name
This field is for validation purposes and should be left unchanged.
Email Address(Required)

More Drug Policy

Prev
1
2
3
4
5
6
7
...
37
Next